Metsera obesity monotherapy data ‘looks competitive,’ says BofA

After Metsera (MTSR) announced results for its ultra long-acting injectable amylin MET-233i for obesity, BofA noted that MET-233i led to weight-loss of 8.4% at the highest dose in the Phase 1, five-week study. The monotherapy data “looks competitive,” though it “seems more likely that amylin+GLP1 combinations will be more important,” adds the analyst, who notes that Metsera is exploring such a combination in the clinic already, with MET-233i co-administered with MET-097. The firm, which reiterates a Buy rating and $38 price target on the stock, says it continues to view Metsera as “the most compelling SMId in obesity.”